<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02111577</url>
  </required_header>
  <id_info>
    <org_study_id>SP005</org_study_id>
    <secondary_id>2012-002814-38</secondary_id>
    <nct_id>NCT02111577</nct_id>
  </id_info>
  <brief_title>Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer</brief_title>
  <acronym>VIABLE</acronym>
  <official_title>A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOTIO a.s.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SOTIO Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VIABLE study sought to confirm the hypothesis that the combination of docetaxel with&#xD;
      DCVAC/PCa followed by a maintenance therapy with DCVAC/PCa would improve overall survival in&#xD;
      patients with metastatic castration-resistant prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double blind, placebo-controlled, multicenter, international,&#xD;
      parallel-group phase III study. Patients with metastatic castration-resistant prostate cancer&#xD;
      who were candidates to receive standard of care first-line chemotherapy with docetaxel plus&#xD;
      prednisone were randomized 2:1 into one of two arms: an investigational arm (DCVAC/PCa) and a&#xD;
      control arm (placebo) in addition to chemotherapy (docetaxel plus prednisone).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 26, 2014</start_date>
  <completion_date type="Actual">January 28, 2020</completion_date>
  <primary_completion_date type="Actual">January 28, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival, Intention-to-treat Population</measure>
    <time_frame>From randomization to death due to any cause, up to 58 months</time_frame>
    <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival, Per Protocol Population</measure>
    <time_frame>From randomization to death due to any cause, up to 58 months</time_frame>
    <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival, Intention-to-treat Population, Abiraterone as Prior Therapy</measure>
    <time_frame>From randomization to death due to any cause, up to 58 months</time_frame>
    <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival, Intention-to-treat Population, Enzalutamide as Prior Therapy</measure>
    <time_frame>From randomization to death due to any cause, up to 58 months</time_frame>
    <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival, Intention-to-treat Population, no Prior Abiraterone or Enzalutamide</measure>
    <time_frame>From randomization to death due to any cause, up to 58 months</time_frame>
    <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological Progression-free Survival, Intention-to-treat Population</measure>
    <time_frame>Time from randomization to the date of the earliest objective evidence of either radiographic progression of bone lesions, radiographic progression of soft tissue lesions, or death due to any cause, up to 58 months</time_frame>
    <description>Progressive disease on bone scans was defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological Progression-free Survival, Per Protocol Population</measure>
    <time_frame>Time from randomization to the date of the earliest objective evidence of either radiographic progression of bone lesions, radiographic progression of soft tissue lesions, or death due to any cause, up to 58 months</time_frame>
    <description>Progressive disease on bone scans was defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Progression, Intention-to-treat Population</measure>
    <time_frame>Time from randomization to the date of objective evidence of PSA progression (PSA absolute increase ≥ 2 ng/mL and ≥ 25% above nadir or baseline values providing confirmation by a second consecutive value obtained at least 3 weeks later), up to 39 months</time_frame>
    <description>The evidence of PSA progression is defined as: time from randomization to the date of PSA absolute increase ≥ 2 ng/mL and ≥ 25% above nadir or baseline values confirmed by a second consecutive value obtained at least 3 weeks later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Progression, Per Protocol Population</measure>
    <time_frame>Time from randomization to the date of objective evidence of PSA progression (PSA absolute increase ≥ 2 ng/mL and ≥ 25% above nadir or baseline values providing confirmation by a second consecutive value obtained at least 3 weeks later), up to 39 months</time_frame>
    <description>The evidence of PSA progression is defined as: time from randomization to the date of PSA absolute increase ≥ 2 ng/mL and ≥ 25% above nadir or baseline values confirmed by a second consecutive value obtained at least 3 weeks later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Skeletal-related Event, Intention-to-treat Population</measure>
    <time_frame>Time from randomization to the date of the first skeletal-related event, up to 58 months</time_frame>
    <description>Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Skeletal-related Event, Per Protocol Population</measure>
    <time_frame>Time from randomization to the date of the first skeletal-related event, up to 58 months</time_frame>
    <description>Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Radiological Progression or Skeletal-related Event, Intention-to-treat Population</measure>
    <time_frame>Time from randomization to the date of the first radiological progression or skeletal-related event, up to 58 months</time_frame>
    <description>Progressive disease on bone scans defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.&#xD;
Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Radiological Progression or Skeletal-related Event, Per Protocol Population</measure>
    <time_frame>Time from randomization to the date of the first radiological progression or skeletal-related event, up to 58 months</time_frame>
    <description>Progressive disease on bone scans defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.&#xD;
Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Skeletal-related Events, Intention-to-treat Population</measure>
    <time_frame>From randomization to the end of the study, up to 57 months</time_frame>
    <description>Progressive disease on bone scans defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.&#xD;
Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Skeletal-related Events, Per Protocol Population</measure>
    <time_frame>From randomization to the end of the study, up to 57 months</time_frame>
    <description>Progressive disease on bone scans defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.&#xD;
Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1182</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>DCVAC/PCa with standard of care chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with standard of care chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVAC/PCa</intervention_name>
    <description>DCVAC/PCa concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). DCVAC/PCa was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of DCVAC/PCa was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.</description>
    <arm_group_label>DCVAC/PCa with standard of care chemotherapy</arm_group_label>
    <other_name>Stapuldencel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). Placebo was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of placebo was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.</description>
    <arm_group_label>Placebo with standard of care chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Male 18 years and older.&#xD;
&#xD;
          -  Histologically or cytologically confirmed prostate adenocarcinoma.&#xD;
&#xD;
          -  Presence of skeletal, or soft-tissue/visceral/nodal metastases according to one of the&#xD;
             following criteria:&#xD;
&#xD;
               -  Confirmed pathological fracture related to the disease OR&#xD;
&#xD;
               -  Confirmation of distant bone and/or soft-tissue and/or visceral metastases on CT&#xD;
                  or MRI scan or bone scintigraphy OR&#xD;
&#xD;
               -  Positive pathology report of metastatic lesion&#xD;
&#xD;
          -  Disease progression despite androgen-deprivation therapy (ADT) as indicated by:&#xD;
&#xD;
               -  Prostate-specific antigen (PSA) increase that is ≥ 2 ng/mL and ≥ 25% above the&#xD;
                  minimum PSA as reached during ADT or above the pre-treatment level, if no&#xD;
                  response was observed and which is confirmed by a second value 1 or more weeks&#xD;
                  later OR&#xD;
&#xD;
               -  Progression of measurable lymph nodes (short axis ≥ 15 mm) or visceral lesion&#xD;
                  measurable per RECIST v1.1 criteria, confirmation by an independent review&#xD;
                  facility (IRF) required OR&#xD;
&#xD;
               -  Two or more new lesions appearing on bone scan/imaging compared with a previous&#xD;
                  scan (confirmation by IRF required)&#xD;
&#xD;
          -  Maintenance of castrate conditions: patients, who have not had a surgical orchiectomy,&#xD;
             must continue with hormone therapy with gonadotropin releasing hormone/ luteinizing&#xD;
             hormone-releasing hormone (GnRH/LHRH) agonists or antagonists to reach levels of serum&#xD;
             testosterone of ≤ 1.7 nmol/L (50 ng/dL). The duration of the castration period must be&#xD;
             at least 4 months before screening as evidenced by combination of clinical/laboratory&#xD;
             data (see section 6.8.1).&#xD;
&#xD;
          -  Laboratory criteria:&#xD;
&#xD;
               -  White blood cells (WBC) greater than 4,000/mm3 (4.0 x109/L)&#xD;
&#xD;
               -  Neutrophil count greater than 1,500/mm3 (1.5 x109/L).&#xD;
&#xD;
               -  Hemoglobin of at least 10 g/dL (100 g/L).&#xD;
&#xD;
               -  Platelet count of at least 100,000/mm3 (100 x 109/L).&#xD;
&#xD;
               -  Total bilirubin within normal limits (benign hereditary hyperbilirubinemias, e.g.&#xD;
                  Gilbert's syndrome, are permitted).&#xD;
&#xD;
               -  Serum alanine aminotransferase, aspartate aminotransferase, and creatinine &lt; 1.5x&#xD;
                  times the upper limit of normal (ULN).&#xD;
&#xD;
          -  Life expectancy of at least 6 months based on Investigator's judgment.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.&#xD;
&#xD;
          -  At least 4 weeks after surgery or radiotherapy before randomization.&#xD;
&#xD;
          -  A minimum of 28 days beyond initiation of bisphosphonate or denosumab therapy before&#xD;
             randomization.&#xD;
&#xD;
          -  Recovery from primary local surgical treatment, radiotherapy or orchiectomy before&#xD;
             randomization.&#xD;
&#xD;
          -  Signed informed consent including patient's ability to comprehend its contents.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Confirmed brain and/or leptomeningeal metastases (other visceral metastases are&#xD;
             acceptable).&#xD;
&#xD;
          -  Current symptomatic spinal cord compression requiring surgery or radiation therapy.&#xD;
&#xD;
          -  Prior chemotherapy for prostate cancer.&#xD;
&#xD;
          -  Patient co-morbidities:&#xD;
&#xD;
               -  Subjects who are not indicated for chemotherapy treatment with first line&#xD;
                  Standard of Care chemotherapy (docetaxel and prednisone).&#xD;
&#xD;
               -  HIV positive, human T-lymphotropic virus positive.&#xD;
&#xD;
               -  Active hepatitis B (active hepatitis B), active hepatitis C (HCV), active&#xD;
                  syphilis.&#xD;
&#xD;
               -  Evidence of active bacterial, viral or fungal infection requiring systemic&#xD;
                  treatment.&#xD;
&#xD;
               -  Clinically significant cardiovascular disease including:&#xD;
&#xD;
                    -  symptomatic congestive heart failure.&#xD;
&#xD;
                    -  unstable angina pectoris.&#xD;
&#xD;
                    -  serious cardiac arrhythmia requiring medication.&#xD;
&#xD;
                    -  uncontrolled hypertension.&#xD;
&#xD;
                    -  myocardial infarction or ventricular arrhythmia or stroke within a 6 months&#xD;
                       before screening, known left ventricular ejection fraction (LVEF) &lt; 40% or&#xD;
                       serious cardiac conduction system disorders, if a pacemaker is not present.&#xD;
&#xD;
               -  Pleural and pericardial effusion of any NCI CTCAE grade.&#xD;
&#xD;
               -  Peripheral neuropathy having a NCI CTCAE ≥ grade 2.&#xD;
&#xD;
               -  History of malignant disease (with the exception of non-melanoma skin tumors) in&#xD;
                  the preceding five years.&#xD;
&#xD;
               -  Active autoimmune disease requiring treatment.&#xD;
&#xD;
               -  History of severe forms of primary immune deficiencies.&#xD;
&#xD;
               -  History of anaphylaxis or other serious reaction following vaccination.&#xD;
&#xD;
               -  Known hypersensitivity to any constituent of the DCVAC/PCa or placebo product.&#xD;
&#xD;
               -  Uncontrolled co-morbidities including, psychiatric or social conditions which, in&#xD;
                  the Investigator's opinion, would prevent participation in the trial.&#xD;
&#xD;
          -  Systemic corticosteroids at doses greater than 40 mg hydrocortisone daily or&#xD;
             equivalent for any reason other than treatment of PCa within 6 months before&#xD;
             randomization.&#xD;
&#xD;
          -  Ongoing systemic immunosuppressive therapy for any reason.&#xD;
&#xD;
          -  Treatment with anti-androgens, inhibitors of adrenal-produced androgens or other&#xD;
             hormonal tumor-focused treatment performed on the day of randomization (except for&#xD;
             GnRH/LHRH agonists or antagonists) to exclude possible anti-androgen withdrawal&#xD;
             response. This criterion is not applicable to subjects who have never responded to&#xD;
             anti-androgen treatment, as there is no risk of anti-androgen withdrawal response.&#xD;
&#xD;
          -  Treatment with immunotherapy against PCa within 6 months before randomization.&#xD;
&#xD;
          -  Treatment with radiopharmaceutical within 8 weeks before randomization.&#xD;
&#xD;
          -  Participation in a clinical trial using non-immunological experimental therapy within&#xD;
             4 weeks before randomization.&#xD;
&#xD;
          -  Participation in a clinical trial using immunological experimental therapy (e.g.,&#xD;
             monoclonal antibodies, cytokines or active cellular immunotherapies) within 6 months&#xD;
             before randomization.&#xD;
&#xD;
          -  Refusal to sign the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas J. Vogelzang</last_name>
    <role>Principal Investigator</role>
    <affiliation>US Oncology Research/Comprehensive Cancer Centers of Nevada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Cancer &amp; Research Centers</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group, Inc.</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research and Excellence</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hao Wei Zhang, MD, LLC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Hematology Oncology Medical Group</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group, Inc.</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Clinical Oncology Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern CT Hematology and Oncololgy Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Miami, Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cancer Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center &amp; Medical Pavilion</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates In Oncology/Hematology,P.C</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GU Research Network</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Research Centers of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Hematology Oncology Associates</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Urology Associates, LLC / AdvanceMed Research</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Health University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Consultants of Southeastern Pennsylvania</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Associates St. Luke's University and Health Network</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Oncology &amp; Hematology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Cancer Center</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Health, Internal Medicine, Division of Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Health Physicians Group</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Network of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Hematology Oncology</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Belvoir Community Hospital</name>
      <address>
        <city>Fort Belvoir</city>
        <state>Virginia</state>
        <zip>22060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Mary Babb Randolph Cancer Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum fur Urologie und Andrologie</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brueder</name>
      <address>
        <city>Wien</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Universitatskrankenhaus Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.N. Alexandrov National Research Center</name>
      <address>
        <city>Lesnoy</city>
        <zip>223040</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minsk City Oncological Hospital</name>
      <address>
        <city>Minsk</city>
        <zip>220013</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique d'Oncologie Medicale Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>01000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital- Urologie</name>
      <address>
        <city>Brussels</city>
        <zip>01070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc- Urologie</name>
      <address>
        <city>Brussels</city>
        <zip>01200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>09000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Department St. Elizabeth Ziekenhuis</name>
      <address>
        <city>Turnhout</city>
        <zip>02300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active treatment in Oncology</name>
      <address>
        <city>Haskovo</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Oncology Hospital</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multifunctional Hospital for Active Treatment Serdika</name>
      <address>
        <city>Sofia</city>
        <zip>1303</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Oncology Diseases</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Varazdin</name>
      <address>
        <city>Varaždin</city>
        <zip>42000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Sisters of Charity</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologicke centrum, Nemocnice Chomutov</name>
      <address>
        <city>Chomutov</city>
        <zip>430 12</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika onkologie a radioterapie, Fakultni nemocnice</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava, urologicke oddeleni</name>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologicke oddeleni, Krajska nemocnice</name>
      <address>
        <city>Liberec</city>
        <zip>46003</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologicka klinika, Fakultni nemocnice</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika onkologicka, Fakultni nemocnice</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Kralovske Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Prague</city>
        <zip>12 808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice</name>
      <address>
        <city>Prague</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska zdravotni, urologicke oddeleni</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>02100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HEGP medical oncology</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Louis IDF Medical Oncology</name>
      <address>
        <city>Paris</city>
        <zip>75 010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital St. Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75 014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cochin, Service de Urologie</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIA Begin</name>
      <address>
        <city>Saint Mandé</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsklinikum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtisches Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtatsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waldkrankenhaus St. Marien</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <zip>60 439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios-Klinik Hamburg-Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinzenkrankenhaus Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30 559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatskinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik Urologie</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtatsklinikum Munster</name>
      <address>
        <city>Münster</city>
        <zip>48 149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienpraxis Urologie</name>
      <address>
        <city>Nürtingen</city>
        <zip>72622</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg AOR</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitastsklinikum Tubingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ammerland Klinik fur Urologie</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxigemeinschaft fur Onkologie und Urologie</name>
      <address>
        <city>Wilhelmshaven</city>
        <zip>26389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Egeszsegugyi Kozpont</name>
      <address>
        <city>Budapest</city>
        <zip>H-1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointeszet</name>
      <address>
        <city>Budapest</city>
        <zip>H-1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bajcsy-Zsilinsky Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>H-1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jasz-Nagykun-Szolnok Megyei</name>
      <address>
        <city>Szolnok</city>
        <zip>H-5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRO Aviano</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Istituti Ospitalieri di Cremona</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Croce e Carle Oespedale</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Roma Sapienza</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedialiera Universitaria Senese</name>
      <address>
        <city>Sienna</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia medica Ospedale S. Vincenzo</name>
      <address>
        <city>Taormina</city>
        <zip>98039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paula Stradina Kliniska Universitates slimnica</name>
      <address>
        <city>Riga</city>
        <zip>LV-1079</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lithuanian University of Health Science Oncology Institute</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipeda University Hospital</name>
      <address>
        <city>Klaipeda</city>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>08 661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Vilnius</city>
        <zip>08660</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhemina Ziekenhuis</name>
      <address>
        <city>Assen</city>
        <zip>9401 RK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tergooi Ziekenhuizen</name>
      <address>
        <city>Hilversum</city>
        <zip>1213 XZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Medisch Centrum</name>
      <address>
        <city>Leeuwarden</city>
        <zip>08934</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St.Radboud</name>
      <address>
        <city>Nijmegen</city>
        <zip>06525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>03079</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Przychodnia Lekarska (KOMED)</name>
      <address>
        <city>Konin</city>
        <zip>62-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital im M.Kopernika</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSTYTUT im. Marii Sklodowskiej-Curie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Ostrobramska</name>
      <address>
        <city>Warszawa</city>
        <zip>04-125</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademicki Szpital Kliniczny im. Jana Mikulicza-Radeckiego</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital da Luz</name>
      <address>
        <city>Lisboa</city>
        <zip>1500-650</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Norte, E.P.E - Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1645-039</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC Zemun</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology and Radiology of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KBC Bezanijska Kosa</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J.Breza MEDICAL s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>851 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologicka ambulancia CUIMED s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>851 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Martin</name>
      <address>
        <city>Martin</city>
        <zip>036 59</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologicka ambulancia Uroexam, spol. s r.o.</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UROX s.r.o.</name>
      <address>
        <city>Piestany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urocentrum MILAB s.r.o.</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatna urologicka ambulancia</name>
      <address>
        <city>Trencin</city>
        <zip>911 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou Zilina</name>
      <address>
        <city>Zilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Príncipe de Asturias</name>
      <address>
        <city>Alcalá de Henares</city>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Sanitarias (IIS), Fundacíon Jimenez Díaz (FJD)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal (CIOCC)</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro de Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Madrid</name>
      <address>
        <city>Pozuelo de Alarcón</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Umeå, Dept Oncology</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebrö</city>
        <zip>SE-701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre</name>
      <address>
        <city>Bebington</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Centre Royal Surrey County Hospital NHS Foundation Trust</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Care, Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Romania</country>
    <country>Turkey</country>
  </removed_countries>
  <link>
    <url>http://www.viablestudy.com</url>
    <description>Click here for more information about this study: Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (VIABLE)</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 9, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2014</study_first_posted>
  <results_first_submitted>January 22, 2021</results_first_submitted>
  <results_first_submitted_qc>March 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2021</results_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Castration-resistant</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Biological</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02111577/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02111577/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
          <description>Combination therapy with dendritic cell vaccine for prostate cancer (DCVAC/PCa) and standard of care chemotherapy (docetaxel and prednisone)</description>
        </group>
        <group group_id="P2">
          <title>Placebo With Standard of Care Chemotherapy</title>
          <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="787"/>
                <participants group_id="P2" count="395"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="599"/>
                <participants group_id="P2" count="289"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to tolerate leukapheresis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to produce study treatment</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="518"/>
                <participants group_id="P2" count="254"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical monitor's decision (active hepatitis B)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
          <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
        </group>
        <group group_id="B2">
          <title>Placebo With Standard of Care Chemotherapy</title>
          <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="787"/>
            <count group_id="B2" value="395"/>
            <count group_id="B3" value="1182"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="272"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="515"/>
                    <measurement group_id="B2" value="288"/>
                    <measurement group_id="B3" value="803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" lower_limit="46" upper_limit="89"/>
                    <measurement group_id="B2" value="69.0" lower_limit="46" upper_limit="89"/>
                    <measurement group_id="B3" value="68.0" lower_limit="46" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="787"/>
                    <measurement group_id="B2" value="395"/>
                    <measurement group_id="B3" value="1182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="733"/>
                    <measurement group_id="B2" value="358"/>
                    <measurement group_id="B3" value="1091"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belarus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="787"/>
                    <count group_id="B2" value="395"/>
                    <count group_id="B3" value="1182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate-specific antigen</title>
          <population>PSA available for 786 patients in the experimental arm (DCVAC/PCa) and 394 patients in the control arm (placebo)</population>
          <units>ng/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="786"/>
                    <count group_id="B2" value="394"/>
                    <count group_id="B3" value="1180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.35" lower_limit="0.0" upper_limit="7500.0"/>
                    <measurement group_id="B2" value="54.02" lower_limit="0.1" upper_limit="5000.0"/>
                    <measurement group_id="B3" value="47.87" lower_limit="0.0" upper_limit="7500.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival, Intention-to-treat Population</title>
        <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
        <time_frame>From randomization to death due to any cause, up to 58 months</time_frame>
        <population>Intention-to-treat population definition: All randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)&#xD;
DCVAC/PCa: DCVAC/PCa concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). DCVAC/PCa was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of DCVAC/PCa was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator&#xD;
Placebo: Placebo concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). Placebo was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of placebo was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival, Intention-to-treat Population</title>
          <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
          <population>Intention-to-treat population definition: All randomized patients</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="787"/>
                <count group_id="O2" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" lower_limit="21.6" upper_limit="25.3"/>
                    <measurement group_id="O2" value="24.3" lower_limit="22.6" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified by region (US vs other), prior abiraterone (Yes vs No), prior enzalutamide (Yes vs No) and Eastern Cooperative Oncology Group (ECOG) score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.596</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.042</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.895</ci_lower_limit>
            <ci_upper_limit>1.213</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.648</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.036</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.891</ci_lower_limit>
            <ci_upper_limit>1.204</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival, Per Protocol Population</title>
        <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
        <time_frame>From randomization to death due to any cause, up to 58 months</time_frame>
        <population>Per protocol population definition:&#xD;
A subset of all randomized patients characterized by the following criteria:&#xD;
had at least 1 post-baseline efficacy assessment&#xD;
did not have any major protocol violation that would affect the endpoints being assessed&#xD;
received at least 8 doses of DCVAC/PCa or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival, Per Protocol Population</title>
          <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
          <population>Per protocol population definition:&#xD;
A subset of all randomized patients characterized by the following criteria:&#xD;
had at least 1 post-baseline efficacy assessment&#xD;
did not have any major protocol violation that would affect the endpoints being assessed&#xD;
received at least 8 doses of DCVAC/PCa or placebo</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="438"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" lower_limit="26.9" upper_limit="32.3"/>
                    <measurement group_id="O2" value="26.7" lower_limit="24.7" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified by region (US vs other), prior abiraterone (Yes vs No), prior enzalutamide (Yes vs No) and ECOG score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.335</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.908</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.746</ci_lower_limit>
            <ci_upper_limit>1.105</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Unstratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.192</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.879</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.725</ci_lower_limit>
            <ci_upper_limit>1.067</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival, Intention-to-treat Population, Abiraterone as Prior Therapy</title>
        <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
        <time_frame>From randomization to death due to any cause, up to 58 months</time_frame>
        <population>Intention-to-treat population definition: All randomized patients with abiraterone as prior therapy</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival, Intention-to-treat Population, Abiraterone as Prior Therapy</title>
          <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
          <population>Intention-to-treat population definition: All randomized patients with abiraterone as prior therapy</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" lower_limit="14.9" upper_limit="19.7"/>
                    <measurement group_id="O2" value="21.0" lower_limit="16.6" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified by region (US vs other), prior enzalutamide (Yes vs No) and ECOG score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.071</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.312</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.976</ci_lower_limit>
            <ci_upper_limit>1.762</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.283</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.961</ci_lower_limit>
            <ci_upper_limit>1.712</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival, Intention-to-treat Population, Enzalutamide as Prior Therapy</title>
        <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
        <time_frame>From randomization to death due to any cause, up to 58 months</time_frame>
        <population>Intention-to-treat population definition: All randomized patients with enzalutamide as prior therapy</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival, Intention-to-treat Population, Enzalutamide as Prior Therapy</title>
          <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
          <population>Intention-to-treat population definition: All randomized patients with enzalutamide as prior therapy</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="13.3" upper_limit="18.3"/>
                    <measurement group_id="O2" value="21.4" lower_limit="15.1" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified by region (US vs other), prior abiraterone (Yes vs No) and ECOG score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.049</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.461</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>2.134</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.436</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.993</ci_lower_limit>
            <ci_upper_limit>2.077</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival, Intention-to-treat Population, no Prior Abiraterone or Enzalutamide</title>
        <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
        <time_frame>From randomization to death due to any cause, up to 58 months</time_frame>
        <population>Intention-to-treat population definition: All randomized patients with neither abiraterone nor enzalutamide as prior therapy</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival, Intention-to-treat Population, no Prior Abiraterone or Enzalutamide</title>
          <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
          <population>Intention-to-treat population definition: All randomized patients with neither abiraterone nor enzalutamide as prior therapy</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" lower_limit="25.2" upper_limit="28.8"/>
                    <measurement group_id="O2" value="25.7" lower_limit="23.8" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified by region (US vs other) and ECOG score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.501</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.938</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.779</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.512</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.781</ci_lower_limit>
            <ci_upper_limit>1.131</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiological Progression-free Survival, Intention-to-treat Population</title>
        <description>Progressive disease on bone scans was defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.</description>
        <time_frame>Time from randomization to the date of the earliest objective evidence of either radiographic progression of bone lesions, radiographic progression of soft tissue lesions, or death due to any cause, up to 58 months</time_frame>
        <population>Intention-to-treat population definition: All randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Radiological Progression-free Survival, Intention-to-treat Population</title>
          <description>Progressive disease on bone scans was defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.</description>
          <population>Intention-to-treat population definition: All randomized patients</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="787"/>
                <count group_id="O2" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="11.0" upper_limit="11.4"/>
                    <measurement group_id="O2" value="11.1" lower_limit="10.8" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified by region (US vs other), prior abiraterone (Yes vs No), prior enzalutamide (Yes vs No) and ECOG score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.886</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.863</ci_lower_limit>
            <ci_upper_limit>1.136</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.992</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.875</ci_lower_limit>
            <ci_upper_limit>1.145</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiological Progression-free Survival, Per Protocol Population</title>
        <description>Progressive disease on bone scans was defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.</description>
        <time_frame>Time from randomization to the date of the earliest objective evidence of either radiographic progression of bone lesions, radiographic progression of soft tissue lesions, or death due to any cause, up to 58 months</time_frame>
        <population>Per protocol population definition:&#xD;
A subset of all randomized patients characterized by the following criteria:&#xD;
had at least 1 post-baseline efficacy assessment&#xD;
did not have any major protocol violation that would affect the endpoints being assessed&#xD;
received at least 8 doses of DCVAC/PCa or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Radiological Progression-free Survival, Per Protocol Population</title>
          <description>Progressive disease on bone scans was defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.</description>
          <population>Per protocol population definition:&#xD;
A subset of all randomized patients characterized by the following criteria:&#xD;
had at least 1 post-baseline efficacy assessment&#xD;
did not have any major protocol violation that would affect the endpoints being assessed&#xD;
received at least 8 doses of DCVAC/PCa or placebo</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="438"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="11.1" upper_limit="11.7"/>
                    <measurement group_id="O2" value="11.2" lower_limit="11.0" upper_limit="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified by region (US vs other), prior abiraterone (Yes vs No), prior enzalutamide (Yes vs No) and ECOG score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.994</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.847</ci_lower_limit>
            <ci_upper_limit>1.184</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.982</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.002</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.851</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PSA Progression, Intention-to-treat Population</title>
        <description>The evidence of PSA progression is defined as: time from randomization to the date of PSA absolute increase ≥ 2 ng/mL and ≥ 25% above nadir or baseline values confirmed by a second consecutive value obtained at least 3 weeks later.</description>
        <time_frame>Time from randomization to the date of objective evidence of PSA progression (PSA absolute increase ≥ 2 ng/mL and ≥ 25% above nadir or baseline values providing confirmation by a second consecutive value obtained at least 3 weeks later), up to 39 months</time_frame>
        <population>Intention-to-treat population definition: All randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PSA Progression, Intention-to-treat Population</title>
          <description>The evidence of PSA progression is defined as: time from randomization to the date of PSA absolute increase ≥ 2 ng/mL and ≥ 25% above nadir or baseline values confirmed by a second consecutive value obtained at least 3 weeks later.</description>
          <population>Intention-to-treat population definition: All randomized patients</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="787"/>
                <count group_id="O2" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="9.7" upper_limit="10.6"/>
                    <measurement group_id="O2" value="10.6" lower_limit="10.4" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified by region (US vs other), prior abiraterone (Yes vs No), prior enzalutamide (Yes vs No) and ECOG score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.392</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.077</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.909</ci_lower_limit>
            <ci_upper_limit>1.277</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.439</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.068</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.905</ci_lower_limit>
            <ci_upper_limit>1.262</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PSA Progression, Per Protocol Population</title>
        <description>The evidence of PSA progression is defined as: time from randomization to the date of PSA absolute increase ≥ 2 ng/mL and ≥ 25% above nadir or baseline values confirmed by a second consecutive value obtained at least 3 weeks later.</description>
        <time_frame>Time from randomization to the date of objective evidence of PSA progression (PSA absolute increase ≥ 2 ng/mL and ≥ 25% above nadir or baseline values providing confirmation by a second consecutive value obtained at least 3 weeks later), up to 39 months</time_frame>
        <population>Per protocol population definition:&#xD;
A subset of all randomized patients characterized by the following criteria:&#xD;
had at least 1 post-baseline efficacy assessment&#xD;
did not have any major protocol violation that would affect the endpoints being assessed&#xD;
received at least 8 doses of DCVAC/PCa or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PSA Progression, Per Protocol Population</title>
          <description>The evidence of PSA progression is defined as: time from randomization to the date of PSA absolute increase ≥ 2 ng/mL and ≥ 25% above nadir or baseline values confirmed by a second consecutive value obtained at least 3 weeks later.</description>
          <population>Per protocol population definition:&#xD;
A subset of all randomized patients characterized by the following criteria:&#xD;
had at least 1 post-baseline efficacy assessment&#xD;
did not have any major protocol violation that would affect the endpoints being assessed&#xD;
received at least 8 doses of DCVAC/PCa or placebo</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="438"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="10.4" upper_limit="10.7"/>
                    <measurement group_id="O2" value="10.6" lower_limit="10.4" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified by region (US vs other), prior abiraterone (Yes vs No), prior enzalutamide (Yes vs No) and ECOG score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.754</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.857</ci_lower_limit>
            <ci_upper_limit>1.238</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.924</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.009</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.844</ci_lower_limit>
            <ci_upper_limit>1.207</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Skeletal-related Event, Intention-to-treat Population</title>
        <description>Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
        <time_frame>Time from randomization to the date of the first skeletal-related event, up to 58 months</time_frame>
        <population>Intention-to-treat population definition: All randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Skeletal-related Event, Intention-to-treat Population</title>
          <description>Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
          <population>Intention-to-treat population definition: All randomized patients</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="787"/>
                <count group_id="O2" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Not reached; insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not reached; insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified by region (US vs other), prior abiraterone (Yes vs No), prior enzalutamide (Yes vs No) and ECOG score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.732</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.918</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.563</ci_lower_limit>
            <ci_upper_limit>1.497</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.713</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.913</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.561</ci_lower_limit>
            <ci_upper_limit>1.485</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Skeletal-related Event, Per Protocol Population</title>
        <description>Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
        <time_frame>Time from randomization to the date of the first skeletal-related event, up to 58 months</time_frame>
        <population>Per protocol population definition:&#xD;
A subset of all randomized patients characterized by the following criteria:&#xD;
had at least 1 post-baseline efficacy assessment&#xD;
did not have any major protocol violation that would affect the endpoints being assessed&#xD;
received at least 8 doses of DCVAC/PCa or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Skeletal-related Event, Per Protocol Population</title>
          <description>Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
          <population>Per protocol population definition:&#xD;
A subset of all randomized patients characterized by the following criteria:&#xD;
had at least 1 post-baseline efficacy assessment&#xD;
did not have any major protocol violation that would affect the endpoints being assessed&#xD;
received at least 8 doses of DCVAC/PCa or placebo</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="438"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Not reached; insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not reached; insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified by region (US vs other), prior abiraterone (Yes vs No), prior enzalutamide (Yes vs No) and ECOG score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.694</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.891</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.587</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.661</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.496</ci_lower_limit>
            <ci_upper_limit>1.562</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Radiological Progression or Skeletal-related Event, Intention-to-treat Population</title>
        <description>Progressive disease on bone scans defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.&#xD;
Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
        <time_frame>Time from randomization to the date of the first radiological progression or skeletal-related event, up to 58 months</time_frame>
        <population>Intention-to-treat population definition: All randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Radiological Progression or Skeletal-related Event, Intention-to-treat Population</title>
          <description>Progressive disease on bone scans defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.&#xD;
Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
          <population>Intention-to-treat population definition: All randomized patients</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="787"/>
                <count group_id="O2" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="10.9" upper_limit="11.3"/>
                    <measurement group_id="O2" value="10.9" lower_limit="10.5" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified by region (US vs other), prior abiraterone (Yes vs No), prior enzalutamide (Yes vs No) and ECOG score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.111</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.895</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.781</ci_lower_limit>
            <ci_upper_limit>1.027</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.184</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.913</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.798</ci_lower_limit>
            <ci_upper_limit>1.044</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Radiological Progression or Skeletal-related Event, Per Protocol Population</title>
        <description>Progressive disease on bone scans defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.&#xD;
Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
        <time_frame>Time from randomization to the date of the first radiological progression or skeletal-related event, up to 58 months</time_frame>
        <population>A subset of all randomized patients characterized by the following criteria:&#xD;
had at least 1 post-baseline efficacy assessment&#xD;
did not have any major protocol violation that would affect the endpoints being assessed&#xD;
received at least 8 doses of DCVAC/PCa or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Radiological Progression or Skeletal-related Event, Per Protocol Population</title>
          <description>Progressive disease on bone scans defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.&#xD;
Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
          <population>A subset of all randomized patients characterized by the following criteria:&#xD;
had at least 1 post-baseline efficacy assessment&#xD;
did not have any major protocol violation that would affect the endpoints being assessed&#xD;
received at least 8 doses of DCVAC/PCa or placebo</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="438"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="11.0" upper_limit="11.5"/>
                    <measurement group_id="O2" value="11.1" lower_limit="10.8" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified by region (US vs other), prior abiraterone (Yes vs No), prior enzalutamide (Yes vs No) and ECOG score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.46</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.939</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.795</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.534</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.807</ci_lower_limit>
            <ci_upper_limit>1.118</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Skeletal-related Events, Intention-to-treat Population</title>
        <description>Progressive disease on bone scans defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.&#xD;
Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
        <time_frame>From randomization to the end of the study, up to 57 months</time_frame>
        <population>Intention-to-treat population definition: All randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Skeletal-related Events, Intention-to-treat Population</title>
          <description>Progressive disease on bone scans defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.&#xD;
Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
          <population>Intention-to-treat population definition: All randomized patients</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="787"/>
                <count group_id="O2" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Adjusted by region (US vs other), prior abiraterone (Yes vs No), prior enzalutamide (Yes vs No) and ECOG score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.485</p_value>
            <method>Log binomial model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.845</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.528</ci_lower_limit>
            <ci_upper_limit>1.355</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Skeletal-related Events, Per Protocol Population</title>
        <description>Progressive disease on bone scans defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.&#xD;
Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
        <time_frame>From randomization to the end of the study, up to 57 months</time_frame>
        <population>A subset of all randomized patients characterized by the following criteria:&#xD;
had at least 1 post-baseline efficacy assessment&#xD;
did not have any major protocol violation that would affect the endpoints being assessed&#xD;
received at least 8 doses of DCVAC/PCa or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
            <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care Chemotherapy</title>
            <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Skeletal-related Events, Per Protocol Population</title>
          <description>Progressive disease on bone scans defined as a minimum of two new lesions. Visceral and nodal disease was evaluated according to RECIST 1.1 with modifications as described in the Statistical Analysis Plan.&#xD;
Skeletal-related events included:&#xD;
Radiation therapy to bone&#xD;
Pathologic bone fracture&#xD;
Spinal cord compression&#xD;
Surgery to bone&#xD;
Change in antineoplastic therapy to treat bone pain</description>
          <population>A subset of all randomized patients characterized by the following criteria:&#xD;
had at least 1 post-baseline efficacy assessment&#xD;
did not have any major protocol violation that would affect the endpoints being assessed&#xD;
received at least 8 doses of DCVAC/PCa or placebo</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="438"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Adjusted by region (US vs other), prior abiraterone (Yes vs No), prior enzalutamide (Yes vs No) and ECOG score (0, 1 vs 2)</non_inferiority_desc>
            <p_value>0.768</p_value>
            <method>Log binomial model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.529</ci_lower_limit>
            <ci_upper_limit>1.601</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 68 months. Adverse events (AEs) occurring after signing the informed consent until 30 days after the last dose of DCVAC/PCa or placebo were collected. Treatment-emergent AEs: Start date on or after the earliest start of chemotherapy or study treatment or adverse event worsened (increased in severity) on or after the earliest start of chemotherapy or study treatment. Deaths: From consent signature to study end.</time_frame>
      <desc>Mortality: in all randomized patients. AEs: in the safety population (received chemotherapy and/or at least 1 dose of DCVAC/PCa or placebo). At each contact, open-ended and non-leading verbal questioning of the patient by the investigator was used to inquire about AEs. Causal relationship of the AE to DCVAC/PCa or placebo was assessed by investigators. Disease progression-related events (as evaluated by investigators) were excluded from serious AE reporting but were captured as non-serious AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>DCVAC/PCa With Standard of Care Chemotherapy</title>
          <description>Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)</description>
        </group>
        <group group_id="E2">
          <title>Placebo With Standard of Care Chemotherapy</title>
          <description>Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="518" subjects_at_risk="787"/>
                <counts group_id="E2" subjects_affected="254" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="237" subjects_at_risk="749"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="749"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Bicytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="749"/>
                <counts group_id="E2" events="34" subjects_affected="29" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="749"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="749"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Enterocolitis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Gastric antral vascular ectasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Rectal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Small intestinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="749"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="749"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Abscess soft tissue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Complicated appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Dermo-hypodermitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cholangitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="749"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Paraspinal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="749"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="749"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="749"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Urinary tract infection staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Viral sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cystitis radiation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Radiation proctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Computerised tomogram abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="749"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Anal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cardiac myxoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Chondrosarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cerebral venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="749"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Superior sagittal sinus thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="749"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Vertigo CNS origin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="749"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Renal atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="749"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="749"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="670" subjects_at_risk="749"/>
                <counts group_id="E2" subjects_affected="365" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="159" subjects_affected="123" subjects_at_risk="749"/>
                <counts group_id="E2" events="96" subjects_affected="76" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="103" subjects_affected="63" subjects_at_risk="749"/>
                <counts group_id="E2" events="74" subjects_affected="33" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="177" subjects_affected="103" subjects_at_risk="749"/>
                <counts group_id="E2" events="92" subjects_affected="54" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="749"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="749"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="133" subjects_affected="111" subjects_at_risk="749"/>
                <counts group_id="E2" events="94" subjects_affected="71" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="338" subjects_affected="204" subjects_at_risk="749"/>
                <counts group_id="E2" events="183" subjects_affected="115" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="44" subjects_at_risk="749"/>
                <counts group_id="E2" events="26" subjects_affected="22" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="196" subjects_affected="150" subjects_at_risk="749"/>
                <counts group_id="E2" events="142" subjects_affected="96" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="54" subjects_affected="39" subjects_at_risk="749"/>
                <counts group_id="E2" events="35" subjects_affected="24" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="97" subjects_affected="78" subjects_at_risk="749"/>
                <counts group_id="E2" events="53" subjects_affected="43" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="156" subjects_affected="106" subjects_at_risk="749"/>
                <counts group_id="E2" events="107" subjects_affected="69" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="374" subjects_affected="268" subjects_at_risk="749"/>
                <counts group_id="E2" events="219" subjects_affected="152" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="33" subjects_affected="28" subjects_at_risk="749"/>
                <counts group_id="E2" events="37" subjects_affected="22" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="146" subjects_affected="121" subjects_at_risk="749"/>
                <counts group_id="E2" events="107" subjects_affected="87" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="104" subjects_affected="76" subjects_at_risk="749"/>
                <counts group_id="E2" events="64" subjects_affected="42" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="749"/>
                <counts group_id="E2" events="26" subjects_affected="22" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="41" subjects_affected="34" subjects_at_risk="749"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="76" subjects_affected="53" subjects_at_risk="749"/>
                <counts group_id="E2" events="66" subjects_affected="39" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="48" subjects_affected="46" subjects_at_risk="749"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="137" subjects_affected="110" subjects_at_risk="749"/>
                <counts group_id="E2" events="102" subjects_affected="79" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="81" subjects_affected="56" subjects_at_risk="749"/>
                <counts group_id="E2" events="41" subjects_affected="27" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="153" subjects_affected="114" subjects_at_risk="749"/>
                <counts group_id="E2" events="110" subjects_affected="74" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="135" subjects_affected="113" subjects_at_risk="749"/>
                <counts group_id="E2" events="79" subjects_affected="67" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="91" subjects_affected="78" subjects_at_risk="749"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="36" subjects_affected="32" subjects_at_risk="749"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="51" subjects_affected="46" subjects_at_risk="749"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="74" subjects_affected="53" subjects_at_risk="749"/>
                <counts group_id="E2" events="47" subjects_affected="32" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="104" subjects_affected="87" subjects_at_risk="749"/>
                <counts group_id="E2" events="74" subjects_affected="55" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="47" subjects_affected="41" subjects_at_risk="749"/>
                <counts group_id="E2" events="40" subjects_affected="33" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="105" subjects_affected="80" subjects_at_risk="749"/>
                <counts group_id="E2" events="91" subjects_affected="59" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="38" subjects_affected="35" subjects_at_risk="749"/>
                <counts group_id="E2" events="33" subjects_affected="27" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="32" subjects_at_risk="749"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="110" subjects_affected="83" subjects_at_risk="749"/>
                <counts group_id="E2" events="59" subjects_affected="54" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="95" subjects_affected="76" subjects_at_risk="749"/>
                <counts group_id="E2" events="42" subjects_affected="33" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="39" subjects_affected="36" subjects_at_risk="749"/>
                <counts group_id="E2" events="31" subjects_affected="28" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="47" subjects_affected="44" subjects_at_risk="749"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Taste disorder</sub_title>
                <counts group_id="E1" events="39" subjects_affected="37" subjects_at_risk="749"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="32" subjects_at_risk="749"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="95" subjects_affected="82" subjects_at_risk="749"/>
                <counts group_id="E2" events="54" subjects_affected="47" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="103" subjects_affected="82" subjects_at_risk="749"/>
                <counts group_id="E2" events="65" subjects_affected="55" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="224" subjects_affected="222" subjects_at_risk="749"/>
                <counts group_id="E2" events="131" subjects_affected="130" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="41" subjects_affected="38" subjects_at_risk="749"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="40" subjects_affected="36" subjects_at_risk="749"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="56" subjects_affected="43" subjects_at_risk="749"/>
                <counts group_id="E2" events="44" subjects_affected="34" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="48" subjects_affected="40" subjects_at_risk="749"/>
                <counts group_id="E2" events="39" subjects_affected="28" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any formal publication of clinical trial results will be a collaborative effort between the sponsor and the investigator(s). All manuscripts or abstracts will be reviewed and approved in written by the sponsor before submission. The sponsor may request a delay in publication if there are important intellectual property concerns but does not have the right to suppress the publication of the clinical trial results indefinitely.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Radek Spisek, M.D., Ph.D.</name_or_title>
      <organization>SOTIO a.s.</organization>
      <phone>+420 2241 75101</phone>
      <email>spisek@sotio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

